

Special Issue

Prion and Prion-Like Diseases

Message from the Guest Editor

As a result of the mad cow crisis and the statement of the prion hypothesis, more than thirty years of research has been dedicated to the exploration of the prion protein, its pathological conversion, and the pathophysiology, diagnosis, and treatment of prion diseases. Furthermore, the "prion concept" has also given rise to the emergence of prion-like diseases, to which many neurodegenerative diseases are now linked as a consequence of, for example, their similarities in protein misfolding and aggregation, cellular pathways triggering neurotoxicity, and common molecular players. The current Special Issue is dedicated to the scientific contributions that highlight prion diseases, prion-like diseases, and the biology of the prion protein. We invite submissions from scientists in the form of review articles or original research papers that are related, but not limited, to the fields of prion and prion-like diseases dealing with the mechanisms of neurodegeneration; misfolded prion biochemistry; protein misfolding; protein aggregation; prion or prion-like propagation; animal models; cell models; diagnosis; treatment; and the etiology of prion/prion-like diseases.

Guest Editor

Dr. Carole Crozet

IRMB, Université de Montpellier, INSERM, CHU de Montpellier, Montpellier, France

Deadline for manuscript submissions

closed (30 November 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/119678

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).